Chai Discovery Raises $70M to Transform Molecular Design
Fundraise follows foundation model breakthrough in fully de novo antibody design with the Chai-2 series of models Menlo Ventures-led round takes total funding to $100M Former Pfizer Chief Scientific Officer Mikael Dolsten, M.D., PhD., joins board Chai Discovery, the AI company that predicts and reprograms the interactions between biochemical molecules to accelerate life-changing therapeutics, today…